Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase

被引：19
作者：
Ahluwalia, R [1 ]
Freimuth, R [1 ]
McLeod, HL [1 ]
Marsh, S [1 ]
机构：
[1] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA
来源：
CLINICAL CHEMISTRY | 2003年 / 49卷 / 10期
关键词：
D O I：
10.1373/49.10.1661
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页码：1661 / 1664
页数：4
相关论文
共 20 条
  • [1] Ando Y, 2000, CANCER RES, V60, P6921
  • [2] Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
    Black, AJ
    McLeod, HL
    Capell, HA
    Powrie, RH
    Matowe, LK
    Pritchard, SC
    Collie-Duguid, ESR
    Reid, DM
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) : 716 - 718
  • [3] The essence of SNPs
    Brookes, AJ
    [J]. GENE, 1999, 234 (02) : 177 - 186
  • [4] Known variant DPYD alleles do not explain DPD deficiency in cancer patients
    Collie-Duguid, ESR
    Etienne, MC
    Milano, G
    McLeod, HL
    [J]. PHARMACOGENETICS, 2000, 10 (03): : 217 - 223
  • [5] Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
    Drysdale, CM
    McGraw, DW
    Stack, CB
    Stephens, JC
    Judson, RS
    Nandabalan, K
    Arnold, K
    Ruano, G
    Liggett, SB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) : 10483 - 10488
  • [6] Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
    Evans, WE
    McLeod, HL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) : 538 - 549
  • [7] Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population
    Hamdy, SI
    Hiratsuka, M
    Narahara, K
    El-Enany, M
    Moursi, N
    Ahmed, MSE
    Mizugaki, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (06) : 596 - 603
  • [8] UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    Iyer L.
    Das S.
    Janisch L.
    Wen M.
    Ramírez J.
    Karrison T.
    Fleming G.F.
    Vokes E.E.
    Schilsky R.L.
    Ratain M.J.
    [J]. The Pharmacogenomics Journal, 2002, 2 (1) : 43 - 47
  • [9] Notes from the SNP vs. haplotype front
    Judson, R
    Stephens, JC
    [J]. PHARMACOGENOMICS, 2001, 2 (01) : 7 - 10
  • [10] PHARMACOGENETICS OF ACUTE AZATHIOPRINE TOXICITY - RELATIONSHIP TO THIOPURINE METHYLTRANSFERASE GENETIC-POLYMORPHISM
    LENNARD, L
    VANLOON, JA
    WEINSHILBOUM, RM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (02) : 149 - 154
12